WQ-3810 inhibits DNA gyrase activity in ofloxacin-resistant Mycobacterium leprae. Issue 4 (April 2020)

• Record Type: Journal Article
• Authors: Park, Jong-Hoon; Yamaguchi, Tomoyuki; Ouchi, Yuki; Koide, Kentaro; Mori, Shigetarou; Kim, Hyun; Mukai, Tetsu; Nakajima, Chie; Suzuki, Yasuhiko
• Is Part Of: Journal of infection and chemotherapy. Volume 26:Issue 4(2020:Apr.)
• Page Start: 335
• Page End: 342
• Publication Date: 2020-04
• Subjects: Mycobacterium leprae -- DNA gyrase -- WQ-3810 -- Recombinant molecules; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2019.10.013
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: Background: Mycobacterium leprae causes leprosy and ofloxacin is used to control this bacterium. However, specific amino acid substitutions in DNA gyrases of M. leprae interferes with the effect of ofloxacin. Methodology/principal findings: Here we tested the inhibitory effect of WQ-3810 on DNA gyrases in M. leprae, using recombinant gyrases. We theorized that WQ-3810 and DNA gyrases interacted, which was tested in silico . Compared with control drugs like ofloxacin, WQ-3810 showed a better inhibitory effect on ofloxacin-resistant DNA gyrases. The in-silico study showed that, unlike control drugs, a specific linkage between a R1 group in WQ-3810 and aspartic acid at position 464 in the subunit B of DNA gyrases existed, which would enhance the inhibitory effect of WQ-3810. This linkage was confirmed in a further experiment, using recombinant DNA gyrases with amino acid substitutions in subunits B instead. Conclusions/significance: The inhibitory effect of WQ-3810 was likely enhanced by the specific linkage between a R1 group residue in its structure and DNA gyrases. Using interactions like the one found in the present work may help design new fluoroquinolones that contribute to halt the emergence of antibiotic-resistant pathogens.